These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 15507634)

  • 1. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
    McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
    J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
    Wyatt LS; Earl PL; Eller LA; Moss B
    Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
    Drexler I; Staib C; Kastenmuller W; Stevanović S; Schmidt B; Lemonnier FA; Rammensee HG; Busch DH; Bernhard H; Erfle V; Sutter G
    Proc Natl Acad Sci U S A; 2003 Jan; 100(1):217-22. PubMed ID: 12518065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.
    Knitlova J; Hajkova V; Voska L; Elsterova J; Obrova B; Melkova Z
    PLoS One; 2014; 9(12):e114374. PubMed ID: 25486419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.
    He Y; Meseda CA; Vassell RA; Merchlinsky M; Weir JP; Weiss CD
    Vaccine; 2010 Jan; 28(3):699-706. PubMed ID: 19887133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.
    Snyder JT; Belyakov IM; Dzutsev A; Lemonnier F; Berzofsky JA
    J Virol; 2004 Jul; 78(13):7052-60. PubMed ID: 15194781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
    Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
    Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
    Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
    J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
    Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
    Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.
    Earl PL; Americo JL; Wyatt LS; Eller LA; Whitbeck JC; Cohen GH; Eisenberg RJ; Hartmann CJ; Jackson DL; Kulesh DA; Martinez MJ; Miller DM; Mucker EM; Shamblin JD; Zwiers SH; Huggins JW; Jahrling PB; Moss B
    Nature; 2004 Mar; 428(6979):182-5. PubMed ID: 15014500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox.
    Kremer M; Suezer Y; Volz A; Frenz T; Majzoub M; Hanschmann KM; Lehmann MH; Kalinke U; Sutter G
    PLoS Pathog; 2012; 8(3):e1002557. PubMed ID: 22396645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
    Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
    Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
    Stittelaar KJ; van Amerongen G; Kondova I; Kuiken T; van Lavieren RF; Pistoor FH; Niesters HG; van Doornum G; van der Zeijst BA; Mateo L; Chaplin PJ; Osterhaus AD
    J Virol; 2005 Jun; 79(12):7845-51. PubMed ID: 15919938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
    Abdalrhman I; Gurt I; Katz E
    Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
    Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
    J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals.
    Lodmell DL; Esposito JJ; Ewalt LC
    Vaccine; 2004 Sep; 22(25-26):3329-33. PubMed ID: 15308356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
    Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
    Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.